Sanofi Appoints Dr. Anne C. Beal to the Newly Created Position
of Chief Patient Officer
– Appointment is a First for a Top 10 Biopharmaceutical Company –
Paris, France – March 31 2014 – Sanofi (EURONEXT: SAN and NYSE: SNY) today announced the appointment of Anne C. Beal, M.D., MPH, to the newly created position of Chief Patient Officer.
« The appointment of a Chief Patient Officer at Sanofi, the first for a top 10 biopharmaceutical company, shows our commitment to go further in meeting the needs of patients », said Pascale Witz, Executive Vice President, Global Divisions and Strategic Development at Sanofi. « Interactions with patients are a source of strength for the company and Dr. Beal’s appointment will help ensure the patient perspective advances our approach to meeting the unmet needs of patients ».
Dr. Beal’s responsibility will be to further elevate the perspective of the patient within Sanofi so the company’s future healthcare offerings can better incorporate the unique priorities and needs of patients and caregivers in a variety of Sanofi activities, ranging from early stage R&D through to on-market availability of novel healthcare solutions.
« I am incredibly honored to join Sanofi as the first Chief Patient Officer», said Dr. Anne C. Beal, M.D., MPH, Chief Patient Officer at Sanofi. « I will use my experience as a physician, researcher, philanthropic leader, and advocate for patient access to high quality care to infuse the patient perspective into Sanofi’s work that will advance our ability to deliver health care solutions that matter most to patients and those who care for them ».
Anne C. Beal, M.D., MPH Biography
Dr. Beal is a pediatrician and public health specialist who has devoted her career to providing access to high-quality health care. She joins Sanofi from the Patient Centered Outcomes Research Institute (PCORI), the United States’ largest research institute focused on patient-centered outcomes research. As PCORI’s Deputy Executive Director, and its first Chief Officer for Engagement, she was charged with ensuring that the voices and priorities of patients and other stakeholders were reflected in the Institute’s research portfolio.
Prior to her tenure with PCORI, Dr. Beal was president of the Aetna Foundation, the independent charitable and philanthropic arm of Aetna Inc. As President, she led the Foundation’s work on improving health care in the United States, particularly for vulnerable patient groups. Dr. Beal holds a B.A. from Brown University, an M.D. from Cornell University Medical College, and an M.P.H. from Columbia University.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2013. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Corporate Media Relations Investor Relations
Laurence Bollack Sébastien Martel
Tel.: +33 1 53 77 46 46 Tel.: + 33 1 53 77 45 45